kurd
𝐂𝐀𝐈 𝐂𝐫𝐞𝐰 𝐌𝐞𝐦𝐛𝐞𝐫
- Joined
- Aug 7, 2023
- Posts
- 2,274
- Reputation
- 3,238
Ritatrutide isn't just helping people shred fat and start to look insane with absolute ease.
It's also reducing anxiety, ADHD symptoms, and addictive behaviors. Now you might be asking, how could this be? Is it just placebo effect? Or is it physiologically possible?
Ritatrutide is so effective as a fat loss agent because it is a triagonist working on three different receptors, the GLP-1, the GIP, and the glucagon receptors.
Now the activity of all these receptors affect dopamine. For the neurological benefits you might be experiencing. The three receptors are also expressed in the brain, not just the body. In particular, GLP-1 receptors are found in areas like the nucleus accumbens, the prefrontal cortex, and the ventral tegmental area.
These are key brain regions involved in dopamine signaling, motivation, and reward. By modulating dopamine in these brain areas, GLP-1 agonists can enhance executive function and impulse control. As well as an improvement in focus and working memory.
This mechanism overlaps with how ADHD stimulants work, which might explain why you're feeling more grounded and focused without your Adderall. GLP-1 and GIP agonism also appear to blunt hedonic reward signals, meaning you're less driven by urges for food, alcohol, nicotine, or even digital stimuli.
Many users report lower emotional reactivity, less binge behavior, and reduced compulsive habits. Behaviors in animal models. In humans, this could be due to lowered inflammation, balanced neurotransmitter levels, and improved gut-brain axis regulation, all of which impact mood and anxiety. Chronic neuroinflammation is linked to ADHD, anxiety, and even addiction.
Retrotrutide's metabolic benefits, namely the improved insulin sensitivity, the reduction in visceral fat, and the enhanced mitochondrial function may also indirectly support better mental health and cognitive clarity.
In summary, retrotrutide's tri-receptor action may help stabilize dopamine, reduce impulsivity, curb cravings, and enhance cognitive function, all of which could help explain the reduced need for stimulants like Adderall and the reported improvements in anxiety and addictive behavior. Human data on retatrutide's neuropsych effects is still limited. We do have data from GLP-1 agonists like semaglutide and liraglutide showing reduced alcohol and nicotine cravings, improved executive functioning, less impulsivity in animal and some human models, and substance use disorders. Retatrutide likely amplifies these benefits because of its potent multi-pathway action.
It's also reducing anxiety, ADHD symptoms, and addictive behaviors. Now you might be asking, how could this be? Is it just placebo effect? Or is it physiologically possible?
Ritatrutide is so effective as a fat loss agent because it is a triagonist working on three different receptors, the GLP-1, the GIP, and the glucagon receptors.
Now the activity of all these receptors affect dopamine. For the neurological benefits you might be experiencing. The three receptors are also expressed in the brain, not just the body. In particular, GLP-1 receptors are found in areas like the nucleus accumbens, the prefrontal cortex, and the ventral tegmental area.
These are key brain regions involved in dopamine signaling, motivation, and reward. By modulating dopamine in these brain areas, GLP-1 agonists can enhance executive function and impulse control. As well as an improvement in focus and working memory.
This mechanism overlaps with how ADHD stimulants work, which might explain why you're feeling more grounded and focused without your Adderall. GLP-1 and GIP agonism also appear to blunt hedonic reward signals, meaning you're less driven by urges for food, alcohol, nicotine, or even digital stimuli.
Many users report lower emotional reactivity, less binge behavior, and reduced compulsive habits. Behaviors in animal models. In humans, this could be due to lowered inflammation, balanced neurotransmitter levels, and improved gut-brain axis regulation, all of which impact mood and anxiety. Chronic neuroinflammation is linked to ADHD, anxiety, and even addiction.
Retrotrutide's metabolic benefits, namely the improved insulin sensitivity, the reduction in visceral fat, and the enhanced mitochondrial function may also indirectly support better mental health and cognitive clarity.
In summary, retrotrutide's tri-receptor action may help stabilize dopamine, reduce impulsivity, curb cravings, and enhance cognitive function, all of which could help explain the reduced need for stimulants like Adderall and the reported improvements in anxiety and addictive behavior. Human data on retatrutide's neuropsych effects is still limited. We do have data from GLP-1 agonists like semaglutide and liraglutide showing reduced alcohol and nicotine cravings, improved executive functioning, less impulsivity in animal and some human models, and substance use disorders. Retatrutide likely amplifies these benefits because of its potent multi-pathway action.
